The Motley Fool Discussion Boards

Previous Page

Industry Discussions / Biotechnology


Subject:  Re: OPTR - CDiff Date:  12/29/2009  8:24 PM
Author:  SarahGen Number:  23845 of 25137

Replying for Fuma - making this thread easier to find.

Someone wiser than me said the following:
"Dr Watson said: "Clostridium difficile costs Europe £1billion a year in healthcare costs. You could view that as saved money or saved beds.""

I think that is a hugely inflated number, and I dont believe there is a vaccine on the horizon that will be heavily used in the US within the next 5-8 years.... however, I do believe that the actual amount spent on antibiotic treatment warrants a market value higher than OPTR is fetching.

what OPTR, or any other CDiff mab maker does NOT need is this: some ICU journal making recommendations against their use the way that the American Diabetes Association recommended against using new agents like Byetta. If an ICU journal puts out a strong rec for it, and an ICU has good results after using it, the medical/surgical floors will soon follow. Its going to be awhile, but just a year ago consider what JPG wrote:

"We haven't had an ICU death in over 6 months since we started giving high dose vanco early and enterally. " ( now, there are numerous reported cases of vanco resistant cdiff.

Copyright 1996-2019 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us